Research analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, January 21st.
Get Our Latest Stock Analysis on VNDA
Vanda Pharmaceuticals Stock Performance
Insider Buying and Selling
In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the sale, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.90% of the company’s stock.
Institutional Trading of Vanda Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the business. Verition Fund Management LLC raised its holdings in Vanda Pharmaceuticals by 7.8% in the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 2,927 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Vanda Pharmaceuticals by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after buying an additional 3,473 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 4,374 shares during the period. Franklin Resources Inc. grew its stake in shares of Vanda Pharmaceuticals by 8.8% in the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 4,449 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 5,459 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Read More
- Five stocks we like better than Vanda Pharmaceuticals
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Sizing Up a New Opportunity for NVIDIA Investors
- How to invest in marijuana stocks in 7 steps
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- What Are Trending Stocks? Trending Stocks Explained
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.